litlas
Log inCreate account

Robert Dreicer

Active 1984–2025

104
Papers
33,183
Citations
75
h-index
100
i10-index

Citations

Citations per year for Robert Dreicer1948: 1 citations1985: 2 citations1986: 2 citations1987: 1 citations1988: 1 citations1989: 1 citations1990: 2 citations1991: 1 citations1993: 1 citations1995: 2 citations1996: 9 citations1997: 17 citations1998: 25 citations1999: 13 citations2000: 17 citations2001: 15 citations2002: 29 citations2003: 27 citations2004: 19 citations2005: 32 citations2006: 27 citations2007: 34 citations2008: 47 citations2009: 108 citations2010: 139 citations2011: 212 citations2012: 205 citations2013: 229 citations2014: 233 citations2015: 213 citations2016: 277 citations2017: 423 citations2018: 455 citations2019: 1,242 citations2020: 1,265 citations2021: 1,347 citations2022: 930 citations2023: 761 citations2024: 1,237 citations2025: 520 citations2026: 17 citations1949–1984: no citations, so these years are not shown1992: no citations, so this year is not shown1994: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,001 citing papers, 26.7% of this breakdownChina: 1,406 citing papers, 9.4% of this breakdownUnited Kingdom: 926 citing papers, 6.2% of this breakdownGermany: 843 citing papers, 5.6% of this breakdownItaly: 815 citing papers, 5.4% of this breakdownFrance: 726 citing papers, 4.9% of this breakdownCanada: 633 citing papers, 4.2% of this breakdownSpain: 501 citing papers, 3.4% of this breakdownJapan: 461 citing papers, 3.1% of this breakdownNetherlands: 430 citing papers, 2.9% of this breakdownAustralia: 422 citing papers, 2.8% of this breakdownSwitzerland: 391 citing papers, 2.6% of this breakdown
0%26.7%Other 22.8%

Institutions

Fields

  • Medicine73.5%
  • Biochemistry, Genetics and Molecular Biology11.5%
  • Immunology and Microbiology11.2%
  • Engineering1.2%
  • Materials Science0.9%
  • Computer Science0.3%
  • Other1.4%

Topics

  • Cancer Immunotherapy and Biomarkers10.1%
  • Prostate Cancer Treatment and Research10.1%
  • Immunotherapy and Immune Responses5.8%
  • Bladder and Urothelial Cancer Treatments5.6%
  • Prostate Cancer Diagnosis and Treatment5.6%
  • Radiopharmaceutical Chemistry and Applications3.5%
  • Other59.3%

Coauthors

All papers

Open in search
  1. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

    Authors: Philip W. Kantoff, Celestia S. Higano, Neal D. Shore, E. Roy Berger, Eric J. Small, David F. Penson, Charles H. Redfern, Anna C. Ferrari, Robert Dreicer, Robert B. Sims, Yi Xu, Mark W. Frohlich, Paul F. Schellhammer - New England Journal of Medicine 2010 cited by 5,492

  2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    Authors: Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer - The Lancet 2016 cited by 3,714

  3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Authors: Howard I. Scher, Michael J. Morris, Walter M. Stadler, Celestia S. Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, Tomasz M. Beer, Michael A. Carducci, Kim N., Paul G. Corn, Johann S. de Bono, Robert Dreicer, Daniel J. George, Elisabeth I. Heath, Maha Hussain, Wm. Kevin Kelly, Glenn Liu, Christopher J. Logothetis, David M. Nanus, Mark N. Stein, Dana E. Rathkopf, Susan F. Slovin, Charles J. Ryan, Oliver Sartor, Eric J. Small, Matthew Raymond Smith, Cora N. Sternberg, Mary-Ellen Taplin, George Wilding, Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 cited by 1,603

  4. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

    Authors: Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Mario A. Eisenberger, Yu-Ning Wong, Noah M. Hahn, Manish Kohli, Matthew M. Cooney, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel H. Shevrin, Maha Hussain, Jorge A. García, Robert S. DiPaola - New England Journal of Medicine 2015 cited by 2,835

  5. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    Authors: Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman‐Censits, José Luis Perez‐Gracia, Nancy A. Dawson, Michiel S. van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta Retz, Richard W. Joseph, Alexandra Drakaki, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. Quinn, Ignacio Durán, David R. Shaffer, Bernhard J. Eigl, Petros Grivas, Evan Y. Yu, Shi Li, Edward E. Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin - The Lancet 2016 cited by 2,211

  6. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

    Authors: Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Noah M. Hahn, Daniel H. Shevrin, Robert Dreicer, Maha Hussain, Mario A. Eisenberger, Manish Kohli, Elizabeth R. Plimack, Nicholas J. Vogelzang, Joel Picus, Matthew M. Cooney, Jorge A. García, Robert S. DiPaola, Christopher J. Sweeney - Journal of Clinical Oncology 2018 cited by 1,106

  7. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

    Authors: Xīn Gào, Howard A. Burris, Jacqueline Vuky, Robert Dreicer, Oliver Sartor, Cora N. Sternberg, Ivor Percent, Maha Hussain, Arash Rezazadeh Kalebasty, John Shen, Elisabeth I. Heath, Guillermo Abesada‐Terk, Sunil Gandhi, Meredith McKean, Haolan Lu, Elmer Berghorn, Richard Gedrich, S. Debbie Chirnomas, Nicholas J. Vogelzang, Daniel P. Petrylak - Journal of Clinical Oncology 2022 cited by 186

  8. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023)

    Authors: William T. Lowrance, Robert Dreicer, David F. Jarrard, Kristen R. Scarpato, Sennett K. Kim, Erin Kirkby, David Buckley, Jessica Griffin, Michael S. Cookson - The Journal of Urology 2023 cited by 290

  9. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

    Authors: Sam S. Chang, Bernard H. Bochner, Roger Chou, Robert Dreicer, Ashish M. Kamat, Seth P. Lerner, Yair Lotan, Joshua J. Meeks, Jeff M. Michalski, Todd M. Morgan, Diane Zipursky Quale, Jonathan E. Rosenberg, Anthony L. Zietman, Jeffrey M. Holzbeierlein - The Journal of Urology 2017 cited by 940

  10. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

    Authors: Matthew D. Galsky, Noah M. Hahn, Jonathan Rosenberg, Guru Sonpavde, Thomas E. Hutson, William Oh, Robert Dreicer, Nicholas J. Vogelzang, Cora N. Sternberg, Dean F. Bajorin, Joaquim Bellmunt - Journal of Clinical Oncology 2011 cited by 688

  11. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

    Authors: Howard I. Scher, Susan Halabi, Ian F. Tannock, Michael J. Morris, Cora N. Sternberg, Michael A. Carducci, Mario A. Eisenberger, Celestia S. Higano, Glenn J. Bubley, Robert Dreicer, Daniel Petrylak, Philip W. Kantoff, Ethan Basch, William Kevin Kelly, William D. Figg, Eric J. Small, Tomasz M. Beer, George Wilding, Alison Martin, Maha Hussain - Journal of Clinical Oncology 2008 cited by 2,241

  12. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer

    Authors: Karen A. Autio, Robert Dreicer, Justine Anderson, Jorge A. García, Ajjai Alva, Lowell L. Hart, Matthew I. Milowsky, Edwin M. Posadas, Charles J. Ryan, Ryon P. Graf, Ryan Dittamore, Nicole A. Schreiber, Jason M. Summa, Hagop Youssoufian, Michael J. Morris, Howard I. Scher - JAMA Oncology 2018 cited by 253

  13. CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors

    Authors: Emmanuel S. Antonarakis, Pedro Isaacsson Velho, Wei Fu, Hao Wang, Neeraj Agarwal, Víctor Sacristán Santos, Benjamin L. Maughan, Роберто Пили, Nabil Adra, Cora N. Sternberg, Panagiotis J. Vlachostergios, Scott T. Tagawa, Alan H. Bryce, Andrea McNatty, Zachery R. Reichert, Robert Dreicer, Oliver Sartor, Tamara L. Lotan, Maha Hussain - JCO Precision Oncology 2020 cited by 206

  14. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

    Authors: Sumanta K. Pal, Bradley McGregor, Cristina Suárez, Che-Kai Tsao, William Kelly, Ulka Vaishampayan, Lance Pagliaro, Benjamin L. Maughan, Yohann Loriot, Daniel Castellano, Sandy Srinivas, Rana R. McKay, Robert Dreicer, Thomas Hutson, Sarita Dubey, Scott Werneke, Ashok Panneerselvam, Dominic Curran, Christian Scheffold, Toni K. Choueiri, Neeraj Agarwal - Journal of Clinical Oncology 2021 cited by 140

  15. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)

    Authors: Neeraj Agarwal, Bradley A. McGregor, Benjamin L. Maughan, Tanya B. Dorff, William Kevin Kelly, Bruno Fang, Rana R. McKay, Parminder Singh, Lance C. Pagliaro, Robert Dreicer, Sandy Srinivas, Yohann Loriot, Ulka N. Vaishampayan, Sanjay Goel, Dominic Curran, Ashok Panneerselvam, Martin Schwickart, Toni K. Choueiri, Sumanta K. Pal - The Lancet Oncology 2022 cited by 66

  16. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

    Authors: Matthew D. Galsky, Noah M. Hahn, Jonathan E. Rosenberg, Guru Sonpavde, Thomas E. Hutson, William Oh, Robert Dreicer, Nicholas J. Vogelzang, Cora N. Sternberg, Dean F. Bajorin, Joaquim Bellmunt - The Lancet Oncology 2011 cited by 345

  17. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I

    Authors: William T. Lowrance, Rodney H. Breau, Roger Chou, Brian F. Chapin, Tony Crispino, Robert Dreicer, David F. Jarrard, Adam S. Kibel, Todd M. Morgan, Alicia K. Morgans, William Oh, Matthew J. Resnick, Anthony L. Zietman, Michael S. Cookson - The Journal of Urology 2020 cited by 266

  18. Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

    Authors: James H. Finke, Brian I. Rini, Joanna Ireland, Patricia Rayman, Amy L. Richmond, Ali Golshayan, Laura S. Wood, Paul Elson, J. Luz Tovar García, Robert Dreicer, Ronald M. Bukowski - Clinical Cancer Research 2008 cited by 485

  19. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

    Authors: Gwénaëlle Gravis, Jean‐Marie Boher, Yu‐Hui Chen, Glenn Liu, Karim Fizazi, Michael A. Carducci, Stéphane Oudard, Florence Joly, David Jarrard, M. Soulié, Mario Eisenberger, Muriel Habibian, Robert Dreicer, Jorge A. García, Maha H.M. Hussain, Manish Kohli, Nicholas J. Vogelzang, Joel Picus, Robert S. DiPaola, Christopher J. Sweeney - European Urology 2018 cited by 247

  20. Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

    Authors: Jennifer S. Ko, Arnold H. Zea, Brian I. Rini, Joanna Ireland, Paul Elson, Peter A. Cohen, Ali Golshayan, Patricia Rayman, Laura S. Wood, Jorge A. García, Robert Dreicer, Ronald M. Bukowski, James H. Finke - Clinical Cancer Research 2009 cited by 852

  21. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma

    Authors: Matthew D. Galsky, G. J. Chen, William Oh, Joaquim Bellmunt, Bruce J. Roth, Roberto Petrioli, Luigi Dogliotti, Robert Dreicer, Guru Sonpavde - Annals of Oncology 2011 cited by 290

  22. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

    Authors: Glenn Heller, Robert McCormack, Thian Kheoh, Arturo Molina, Matthew R. Smith, Robert Dreicer, Fred Saad, Ronald de Wit, Dana T. Aftab, Mohammad Hirmand, Ana Limon, Karim Fizazi, Martin Fleisher, Johann S. de Bono, Howard I. Scher - Journal of Clinical Oncology 2017 cited by 230

  23. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)

    Authors: Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, Nabil Adra, Jingsong Zhang, Channing J. Paller, Joel Picus, Zachery R. Reichert, Russell Z. Szmulewitz, Scott T. Tagawa, Timothy M. Kuzel, Latifa A. Bazzi, Stephanie Daignault‐Newton, Young E. Whang, Robert Dreicer, Ryan D. Stephenson, Matthew B. Rettig, Daniel H. Shevrin, Travis Gerke, Arul M. Chinnaiyan, Emmanuel S. Antonarakis - Clinical Cancer Research 2024 cited by 44

  24. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel

    Authors: Lauren C. Harshman, Yu‐Hui Chen, Glenn Liu, Michael A. Carducci, David F. Jarrard, Robert Dreicer, Noah M. Hahn, Jorge A. García, Maha Hussain, Daniel H. Shevrin, Mario A. Eisenberger, Manish Kohli, Elizabeth R. Plimack, Matthew M. Cooney, Nicholas J. Vogelzang, Joel Picus, Robert S. DiPaola, Christopher J. Sweeney, on behalf of the ECOG-ACRIN 3805 Investigators - Journal of Clinical Oncology 2017 cited by 123